酮替芬联合舒利迭治疗支气管哮喘44例  

Ketotifen Combined with Seretide for Treating Bronchial Asthma in 44 Cases

作　　者：聂川江[1] 何文富[1] 曾永保[1] 

机构地区：[1]四川省宜宾市第一人民医院药剂科,四川宜宾644000

出　　处：《中国药业》2014年第7期66-67,共2页China Pharmaceuticals

摘　　要：目的观察酮替芬联合舒利迭治疗支气管哮喘的疗效。方法将87例支气管哮喘患者按随机数字表法分为两组,治疗组44例予以酮替芬联合舒利迭治疗,对照组43例予以孟鲁司特联合舒利迭治疗,均治疗12周后进行哮喘控制评分、测定第1秒用力呼气容积占预计值的百分比(FEV1%)、呼气流量峰值(PEF)和药品不良反应(ADR)。结果与对照组比较,治疗组能显著提高哮喘患者的控制测试评分(P<0.05);两组治疗后FEV1%和PEF较治疗前均有显著提高,但两组比较差异无统计学意义;两组ADR发生率分别为6.82%和9.30%,差异无统计学意义。结论酮替芬联合舒利迭治疗支气管哮喘的综合疗效优于孟鲁司特联合舒利迭,且经济、安全,可作为孟鲁司特的替代药物用于治疗支气管哮喘。Objective To observe the efficacy of ketotifen combined with seretide in treating bronchial asthma. Methods Eighty- seven screened patients with bronchial asthma were divided into the treatment group and the control group according to the random number table. Forty-four cases in the treatment group were treated with ketotifen combined with seretide; 43 cases in the control group were treated with montelukast combined with seretide. After 12-week treatment, the asthma control scores, forced expiratory volume in one second（FEV1% ）, peak expiratory flow（PEF） were detected and the adverse drug reactions（ADR） were observed in each group. Results Compared with the control group, the asthma control scores in the treatment group were significantly improved（ P〈0.05）; FEV,% and PEF after treatment in the two groups were significantly increased than before treatment, but the difference between the two groups had no statistical significance; the occurrence rates of ADR in the two groups were 6. 82% and 9.30% respectively, but the difference between the two groups had no statistically significant. Conclusion The overall efficacy of ketotifen combined with seretide is better than that of montelukast combined with seretide in treating of bronchial asthma. Ketotifen is safe and cheap, which can replace mon- telukast in treatin~ bronchial asthma.

关 键 词：酮替芬 舒利迭 孟鲁司特 支气管哮喘 丘-斯二氏综合征 

分 类 号：R969.4[医药卫生—药理学] R974[医药卫生—药学]